Cargando…

Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs

The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Axiak‐Bechtel, Sandra M., Leach, Stacey B., Scholten, David G., Newton‐Northup, Jessica R., Johnson, Brendan J., Durham, H. E., Gruber, Kenneth A., Callahan, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135083/
https://www.ncbi.nlm.nih.gov/pubmed/34014033
http://dx.doi.org/10.1002/prp2.777
_version_ 1783695299663888384
author Axiak‐Bechtel, Sandra M.
Leach, Stacey B.
Scholten, David G.
Newton‐Northup, Jessica R.
Johnson, Brendan J.
Durham, H. E.
Gruber, Kenneth A.
Callahan, Michael F.
author_facet Axiak‐Bechtel, Sandra M.
Leach, Stacey B.
Scholten, David G.
Newton‐Northup, Jessica R.
Johnson, Brendan J.
Durham, H. E.
Gruber, Kenneth A.
Callahan, Michael F.
author_sort Axiak‐Bechtel, Sandra M.
collection PubMed
description The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐dose TCMCB07 (0.75 mg kg(−1)) (n = 5) once daily for 28 days with a 14‐day washout period between groups. Histamine levels, complete blood count, chemistry panel, blood pressure, 24‐hour Holter recording, and pharmacokinetic parameters were monitored in the high‐dose group. Physical examination changes were limited to weight gain and darkening of the coat color. There was no elevation of plasma histamine within 24 hours of injection but there was a significant elevation of plasma histamine across time. An approximately doubled eosinophil count and an approximately 25% increase, and then 25% decrease back to pre‐treatment plasma phosphorous were also found, although both remained within the reference interval. Serial blood pressure and 24‐hour Holter monitors revealed no clinically relevant changes. A difference was found in the AUC between dosing groups and a significant effect of dose, time, and interaction was noted for V(d). Low‐dose TCMCB07 had a C(max) of 2.1 ug ml(−1) at day 28, compared to high‐dose TCMCB07 which had a C(max) 3.6 ug ml(−1) at day 28. Once‐daily subcutaneous administration of TCMCB07 was well‐tolerated for up to 28 days in dogs when administered at doses one and three times (0.75 mg kg(−1) and 2.25 mg kg(−1)) the predicted therapeutic dose and pharmacokinetic parameters are described. SIGNIFICANCE STATEMENT: Melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 is safe at both low and high doses in dogs. Therapy was tolerated well as determined by physical examination, clinical pathology, and cardiovascular parameters; darkening of the coat was noted with treatment and resolved with discontinuation. Pharmacokinetics are described and further study in the naturally occurring canine model is warranted.
format Online
Article
Text
id pubmed-8135083
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81350832021-05-21 Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs Axiak‐Bechtel, Sandra M. Leach, Stacey B. Scholten, David G. Newton‐Northup, Jessica R. Johnson, Brendan J. Durham, H. E. Gruber, Kenneth A. Callahan, Michael F. Pharmacol Res Perspect Original Articles The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐dose TCMCB07 (0.75 mg kg(−1)) (n = 5) once daily for 28 days with a 14‐day washout period between groups. Histamine levels, complete blood count, chemistry panel, blood pressure, 24‐hour Holter recording, and pharmacokinetic parameters were monitored in the high‐dose group. Physical examination changes were limited to weight gain and darkening of the coat color. There was no elevation of plasma histamine within 24 hours of injection but there was a significant elevation of plasma histamine across time. An approximately doubled eosinophil count and an approximately 25% increase, and then 25% decrease back to pre‐treatment plasma phosphorous were also found, although both remained within the reference interval. Serial blood pressure and 24‐hour Holter monitors revealed no clinically relevant changes. A difference was found in the AUC between dosing groups and a significant effect of dose, time, and interaction was noted for V(d). Low‐dose TCMCB07 had a C(max) of 2.1 ug ml(−1) at day 28, compared to high‐dose TCMCB07 which had a C(max) 3.6 ug ml(−1) at day 28. Once‐daily subcutaneous administration of TCMCB07 was well‐tolerated for up to 28 days in dogs when administered at doses one and three times (0.75 mg kg(−1) and 2.25 mg kg(−1)) the predicted therapeutic dose and pharmacokinetic parameters are described. SIGNIFICANCE STATEMENT: Melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 is safe at both low and high doses in dogs. Therapy was tolerated well as determined by physical examination, clinical pathology, and cardiovascular parameters; darkening of the coat was noted with treatment and resolved with discontinuation. Pharmacokinetics are described and further study in the naturally occurring canine model is warranted. John Wiley and Sons Inc. 2021-05-20 /pmc/articles/PMC8135083/ /pubmed/34014033 http://dx.doi.org/10.1002/prp2.777 Text en © 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Axiak‐Bechtel, Sandra M.
Leach, Stacey B.
Scholten, David G.
Newton‐Northup, Jessica R.
Johnson, Brendan J.
Durham, H. E.
Gruber, Kenneth A.
Callahan, Michael F.
Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
title Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
title_full Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
title_fullStr Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
title_full_unstemmed Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
title_short Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
title_sort pharmacokinetics and safety of tcmcb07, a melanocortin‐4 antagonist peptide in dogs
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135083/
https://www.ncbi.nlm.nih.gov/pubmed/34014033
http://dx.doi.org/10.1002/prp2.777
work_keys_str_mv AT axiakbechtelsandram pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs
AT leachstaceyb pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs
AT scholtendavidg pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs
AT newtonnorthupjessicar pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs
AT johnsonbrendanj pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs
AT durhamhe pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs
AT gruberkennetha pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs
AT callahanmichaelf pharmacokineticsandsafetyoftcmcb07amelanocortin4antagonistpeptideindogs